Shire plc / FerroKin BioSciences, Inc.

Transfusional Iron Overload (Beta-Thalassemia / MDS)

$900M Global iron chelation market (~2012, annual)

Disease Overview

Patients receiving chronic blood transfusions for beta-thalassemia, MDS, and sickle cell disease accumulate iron in vital organs because the human body cannot excrete excess iron. Untreated iron overload causes liver, cardiac, and endocrine organ failure and is the leading cause of death in transfusion-dependent thalassemia. Oral iron chelators are the standard of care but tolerability and dosing burden remain major issues.

Competitive Landscape

The 2012 oral iron chelation market was dominated by Novartis' Exjade (deferasirox), launched in 2005 as the first oral alternative to injected Desferal (deferoxamine) and reaching ~$850M in 2011 sales. Apotex's Ferriprox (deferiprone) had niche US approval as a second-line option after FDA approval in October 2011. Desferal remained the legacy injectable used overnight via subcutaneous pump. Shire's bet on FBS0701 (renamed SPD602) was that a once-daily capsule could differentiate against Exjade's dispersible-tablet slurry that many patients struggle to tolerate, with preclinical data showing a >=4-fold higher no-observed-adverse-effect level versus deferasirox. The acquisition strengthened Shire's hematology pipeline alongside Replagal and the firm's specialty rare-disease franchise. Analysts noted Shire would 'need to show clear water' between FBS0701 and Exjade to take share. The asset was ultimately deprioritized after Shire missed development milestones, leading to a 2021 Delaware Chancery ruling forcing Shire to pay $45M of contingent milestones to former FerroKin holders.